SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression

Mesenchymal stem cells (MSCs) contribute to tumor pathogenesis and elicit antitumor immune responses in tumor microenvironments. Nuclear proteins might be the main players in these processes. In the current study, combining spatial proteomics with ingenuity pathway analysis (IPA) in lung non-small c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Libang, Yang, Jianbo, Jacobson, Blake, Gilbertsen, Adam, Smith, Karen, Higgins, LeeAnn, Guerrero, Candace, Xia, Hong, Henke, Craig A., Lin, Jizhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190464/
https://www.ncbi.nlm.nih.gov/pubmed/35707369
http://dx.doi.org/10.3389/fonc.2022.862250
_version_ 1784725795043803136
author Yang, Libang
Yang, Jianbo
Jacobson, Blake
Gilbertsen, Adam
Smith, Karen
Higgins, LeeAnn
Guerrero, Candace
Xia, Hong
Henke, Craig A.
Lin, Jizhen
author_facet Yang, Libang
Yang, Jianbo
Jacobson, Blake
Gilbertsen, Adam
Smith, Karen
Higgins, LeeAnn
Guerrero, Candace
Xia, Hong
Henke, Craig A.
Lin, Jizhen
author_sort Yang, Libang
collection PubMed
description Mesenchymal stem cells (MSCs) contribute to tumor pathogenesis and elicit antitumor immune responses in tumor microenvironments. Nuclear proteins might be the main players in these processes. In the current study, combining spatial proteomics with ingenuity pathway analysis (IPA) in lung non-small cell (NSC) cancer MSCs, we identify a key nuclear protein regulator, SFPQ (Splicing Factor Proline and Glutamine Rich), which is overexpressed in lung cancer MSCs and functions to promote MSCs proliferation, chemical resistance, and invasion. Mechanistically, the knockdown of SFPQ reduces CD44v6 expression to inhibit lung cancer MSCs stemness, proliferation in vitro, and metastasis in vivo. The data indicates that SFPQ may be a potential therapeutic target for limiting growth, chemotherapy resistance, and metastasis of lung cancer.
format Online
Article
Text
id pubmed-9190464
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91904642022-06-14 SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression Yang, Libang Yang, Jianbo Jacobson, Blake Gilbertsen, Adam Smith, Karen Higgins, LeeAnn Guerrero, Candace Xia, Hong Henke, Craig A. Lin, Jizhen Front Oncol Oncology Mesenchymal stem cells (MSCs) contribute to tumor pathogenesis and elicit antitumor immune responses in tumor microenvironments. Nuclear proteins might be the main players in these processes. In the current study, combining spatial proteomics with ingenuity pathway analysis (IPA) in lung non-small cell (NSC) cancer MSCs, we identify a key nuclear protein regulator, SFPQ (Splicing Factor Proline and Glutamine Rich), which is overexpressed in lung cancer MSCs and functions to promote MSCs proliferation, chemical resistance, and invasion. Mechanistically, the knockdown of SFPQ reduces CD44v6 expression to inhibit lung cancer MSCs stemness, proliferation in vitro, and metastasis in vivo. The data indicates that SFPQ may be a potential therapeutic target for limiting growth, chemotherapy resistance, and metastasis of lung cancer. Frontiers Media S.A. 2022-05-30 /pmc/articles/PMC9190464/ /pubmed/35707369 http://dx.doi.org/10.3389/fonc.2022.862250 Text en Copyright © 2022 Yang, Yang, Jacobson, Gilbertsen, Smith, Higgins, Guerrero, Xia, Henke and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Libang
Yang, Jianbo
Jacobson, Blake
Gilbertsen, Adam
Smith, Karen
Higgins, LeeAnn
Guerrero, Candace
Xia, Hong
Henke, Craig A.
Lin, Jizhen
SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression
title SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression
title_full SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression
title_fullStr SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression
title_full_unstemmed SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression
title_short SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression
title_sort sfpq promotes lung cancer malignancy via regulation of cd44 v6 expression
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190464/
https://www.ncbi.nlm.nih.gov/pubmed/35707369
http://dx.doi.org/10.3389/fonc.2022.862250
work_keys_str_mv AT yanglibang sfpqpromoteslungcancermalignancyviaregulationofcd44v6expression
AT yangjianbo sfpqpromoteslungcancermalignancyviaregulationofcd44v6expression
AT jacobsonblake sfpqpromoteslungcancermalignancyviaregulationofcd44v6expression
AT gilbertsenadam sfpqpromoteslungcancermalignancyviaregulationofcd44v6expression
AT smithkaren sfpqpromoteslungcancermalignancyviaregulationofcd44v6expression
AT higginsleeann sfpqpromoteslungcancermalignancyviaregulationofcd44v6expression
AT guerrerocandace sfpqpromoteslungcancermalignancyviaregulationofcd44v6expression
AT xiahong sfpqpromoteslungcancermalignancyviaregulationofcd44v6expression
AT henkecraiga sfpqpromoteslungcancermalignancyviaregulationofcd44v6expression
AT linjizhen sfpqpromoteslungcancermalignancyviaregulationofcd44v6expression

Ejemplares similares